CAP

Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics

Thursday, October 21, 2021 - 5:00pm

MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.

Key Points: 
  • MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.
  • According to a recent publication reporting data from the largest independent psoriasis registry (CorEvitas),1 real-world patient response rates to hyper-expensive biologics were observed to be approximately 52%.
  • These low response rates often lead to switching of therapies and massive wasted healthcare spending.
  • Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin.

Research Demonstrates Old-Fashioned Toothbrush Performs Better than Modern Versions

Thursday, October 21, 2021 - 4:00pm

Older toothbrushes have a flat bristle design compared to todays versions which tend to be uneven.

Key Points: 
  • Older toothbrushes have a flat bristle design compared to todays versions which tend to be uneven.
  • Because the Sound Feelings brand toothbrush has the lowest wear index, it is more effective in removing plaque and preventing tooth decay for longer periods of time.
  • A bonus benefit is that the traditional flat, slim handles fit in wall toothbrush holders, while the newer brushes do not.
  • Sound Feelings toothbrushes are available from the Plain Toothbrush website www.plain-toothbrush.com as well as Amazon, eBay, and ToothbrushExpress.

FDA Grants Breakthrough Device Designation for Biological Dynamics’ Early-stage Pancreatic Cancer Detection Test

Wednesday, October 20, 2021 - 9:00pm

The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.

Key Points: 
  • The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.
  • Early detection of pancreatic cancer in elevated risk individuals may help save a lot of lives, said Scott Lippman, MD, Director of Moores Cancer Center at UC San Diego Health.
  • The promise of Biological Dynamics cutting-edge exosomal isolation technology is addressing a critical, unmet medical need in our multidisciplinary and multi-dimensional fight against pancreatic cancer.
  • Exo-PDAC is the first assay to use Biological Dynamics Verita platform, a novel alternating current electrokinetic-based technology applied for early disease detection, including cancer, Alzheimers disease, and infectious diseases.

Granite Awarded $19 Million Runway Repair at Cannon AFB

Tuesday, October 19, 2021 - 10:30pm

Granite (NYSE:GVA) announced the award of a runway repair project at Cannon Air Force Base (AFB) by the Albuquerque District of the U.S. Army Corps of Engineers (USACE).

Key Points: 
  • Granite (NYSE:GVA) announced the award of a runway repair project at Cannon Air Force Base (AFB) by the Albuquerque District of the U.S. Army Corps of Engineers (USACE).
  • Located in Curry County, on New Mexicos high eastern plains, Cannon AFB is home to units of the Air Force Special Operations Command.
  • The $19 million contract is anticipated to be included in Granites fourth quarter committed and awarded projects (CAP).
  • Granites scope of work consists of a four-inch-deep mill and asphalt concrete overlay of Runway 13/31, the construction of new 25-foot shoulders along the entire 1.5-mile runway, installation of runway lighting, threshold lighting, and a counterpoise system.

Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays

Tuesday, October 19, 2021 - 12:00pm

Research Triangle Park, NC, USA and Cambridge, UK, 19 October 2021 -- Inivata, a leader in liquid biopsy, today announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.

Key Points: 
  • Research Triangle Park, NC, USA and Cambridge, UK, 19 October 2021 -- Inivata, a leader in liquid biopsy, today announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivatas liquid biopsy assays, InVisionFirst-Lung and RaDaR in two separate studies.
  • The first phase, DETECT, will screen 360 early-stage lung cancer patients to assess the rate of pre- and post-operative ctDNA levels using RaDaR.
  • Dr. Natasha Leighl, Lung Site Lead, Medical Oncology, Princess Margaret Cancer Center, said: Liquid biopsy technologies have the potential to transform cancer treatment, getting patients to the right treatment faster and increasing the chances of a cure.
  • Inivatas InVision liquid biopsy platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse.

Cooperative of American Physicians Announces Retirement of General Counsel Gordon T. Ownby; CAP Associate General Counsel Douglas Shin Named as Successor

Monday, October 18, 2021 - 3:00pm

He began serving CAP physicians in 1987 as a defense attorney in CAPs dedicated law firm, Schmid & Voiles, and became CAPs general counsel in 1992.

Key Points: 
  • He began serving CAP physicians in 1987 as a defense attorney in CAPs dedicated law firm, Schmid & Voiles, and became CAPs general counsel in 1992.
  • At the time of his retirement, he will have contributed more than 260 columns to the newsletter.
  • Mr. Ownby will be succeeded by Douglas Shin, who is currently Associate General Counsel and has worked at CAP since 2012.
  • The Cooperative of American Physicians, Inc. (CAP), established in 1975, offers medical professional liability protection to some 12,000 of California's finest physicians through the Mutual Protection Trust.

Plexision Receives Laboratory Accreditation by the College of American Pathologists

Monday, October 18, 2021 - 2:37pm

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the governments own inspection program.

Key Points: 
  • The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the governments own inspection program.
  • CAP accreditation validates this commitment and is an important and well-deserved milestone for our team, said Rajeev Sindhi, CEO of Plexision.
  • About Plexision: Plexisions reference laboratory performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology.
  • As the worlds largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

(ISC)² to Address Cybersecurity Workforce Gap with New Entry-Level Cybersecurity Certification Pilot Program

Monday, October 18, 2021 - 2:10pm

The new qualification will support cybersecurity career ambitions and help shape a long-term professional development framework that leads individuals to experience-driven certifications as they progress in the workforce.

Key Points: 
  • The new qualification will support cybersecurity career ambitions and help shape a long-term professional development framework that leads individuals to experience-driven certifications as they progress in the workforce.
  • As a foundational certification, it will play a role in helping employers, educators and governments close the cybersecurity workforce shortage by narrowing the gap between entering the workforce and being able to verify and advance skills through independent and globally recognized industry qualifications.
  • Additionally, the new entry-level qualification will provide more clarity for candidates who aspire to obtain the CISSP credential.
  • The pilot program for the new qualification will follow the conclusion of the JTA survey of cybersecurity practitioners, which is open through October 20, 2021.

New (ISC)² Research Reveals the Challenges and Opportunities Associated with Diversity, Equity and Inclusion in the Cybersecurity Community

Monday, October 18, 2021 - 2:05pm

The study outlines eight recommendations for improving DEI in cybersecurity teams, from implementing cultural sensitivity training to documenting clear advancement practices.

Key Points: 
  • The study outlines eight recommendations for improving DEI in cybersecurity teams, from implementing cultural sensitivity training to documenting clear advancement practices.
  • "What we found is that many issues are universal to the experiences of diverse professionals no matter where they live and work.
  • Following is a small selection of the respondents' firsthand accounts and advice in the report:
    "The diversity of thought is a global crisis.
  • I mean, it needs to be in the cybersecurity workforce or else nothing's going to be secure in this world."

Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT)

Monday, October 18, 2021 - 2:12pm

SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inherent Biosciences , a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the launch of Path Fertility's Epigenetic Sperm Quality Test, SpermQTTM at the American Society for Reproductive Medicine Scientific Congress & Expo.

Key Points: 
  • SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inherent Biosciences , a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the launch of Path Fertility's Epigenetic Sperm Quality Test, SpermQTTM at the American Society for Reproductive Medicine Scientific Congress & Expo.
  • SpermQT analyzes epigenetic patterns (DNA methylation) on genes associated with sperm production, sperm maturation, and embryo development.
  • "We now have a diagnostic that significantly improves the measurement of sperm quality," said Alex Pastuszak, MD, Ph.D., Inherent Biosciences clinical advisor.
  • About Inherent Biosciences - Inherent Biosciences, Inc. is a molecular diagnostics company at the intersection of epigenetics and AI.